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Aims: Long-term prescription of N-acetyl cysteine (NAC) may be effective in diseases
caused by active radicals of oxygen species. The aim of this study was to determine the
effect of 2- and 4-month administration of NAC (1800mg daily) on mustard induced
bronchiolitis obliterans.
Methods and materials: In a double blind clinical trial, 144 patients with bronchiolitis
obliterans due to sulfur mustard in bronchiolitis obliterans syndrome (BOS) classes 1 and 2,
randomly entered Group 1 (n ¼ 72, NAC) and Group 2 (n ¼ 72, placebo). Dyspnea, wake-up
dyspnea, cough, and sputum were measured after 4 months. Spirometric findings were
measured at the beginning of the trial, 2 months after and after 4 months of prescription of
1800mg/day in three doses of NAC or placebo.
Results: Dyspnea, cough, sputum, and wake-up dyspnea improved after 4 months of NAC
compared to the control group. After 4 months, spirometric components were significantly
improved in NAC group compared to placebo group.
Conclusion: Fourth months administration of NAC (1800mg daily) can improve clinical
conditions and spirometric findings in mustard exposed in BOS class 1 or 2.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
88053770;
com, m.ghanei@bmsu.ac.irIntroduction
Nowadays there are more than 40,000 people suffering from
pulmonary lesions due to mustard gas in Iran.1 There is not a
common consensus about the pathophysiological basis of
chronic lesions of mustard gas2,3; but there is a huge body of
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mentioned as basis.4–7 So a progressive process could be
assumed at the heart of its pathology. Some studies showed
that mustard induced mustard lesions, like some other
diseases are a neutrophil and/or lymphocyte dominant
disorder (e.g. neutrophil dominated inflammatory disease).8
Among the theories trying to explain these disorders, one
suggests that neutrophils and lymphocytes secret proteases
which themselves produce oxygen species.8
In order to treat patients with mustard induced pulmon-
ary disorders, they received bronchodilators, corticoster-
oids, immunosuppressive, antibiotics, mucolytics, long-term
oxygen therapy and physiotherapy.1 These treatments have
known side effects. For example, long-term administration
of corticosteroids could suppress adrenal which in turn
causes diabetes mellitus, osteoporosis, sodium retention,
and many other disorders.9 In parallel, these patients do not
respond well to bronchodilators. So it is reasonable to look
for new drugs and protocols in order to substitute the old
treatments with new ones.
By considering the roles of oxygen species and free
radicals in the pathophysiology of mustard induced pulmon-
ary lesions, it is useful to consider antioxidant drugs in
treating these patients.8 N-acetyl cysteine (NAC) is categor-
ized in mucolytic drugs but it also has antioxidant effects. It
is used in patients with COPD and asthma to reduce signs and
symptoms and improves pulmonary function tests (PFTs) and
quality of life.10,11 It also has good therapeutic effects in
fibrozing alveolitis.12 Kasielski and Nowak13 showed that
administering NAC, 600mg daily for 12 months in patients
with COPD, reduced oxidative stress. There are also some
other results in the same line.14,15
NAC can reduce the oxidative burst of polymorphonuclear
(PMN) cells in COPD patients.16 It is also proposed that it
could protect pulmonary cells from inhaled oxidants and
also cytokine made ones.17 NAC could have protective
effects on peripheral granulocytes in COPD patients too.18 It
is shown that NAC reduces the number of neutrophils in mice
which were exposed to sulfur mustard and developed lung
injuries.19
So NAC could be a good alternative treatment in patients
suffering pulmonary disorders due to mustard gas. NAC could
be helpful with its antioxidant and also antimucolytic
activities. In this trial, we tried to evaluate the therapeutic
effects of NAC on late sequels of mustard induced
pulmonary bronchiolitis obliterans.Methods
In order to test the effects of NAC on pulmonary disorders
due to mustard gas, we ran a placebo controlled, double
blind, randomized clinical trial. Participants were among
patients who suffer from pulmonary disorders due to sulfur
mustard exposure. They were all from Sardasht, a city in the
west of Iran; they were exposed to a single high dose of
sulfur mustard in the Iran–Iraq conflict in 1988. So
administering the NAC or placebo was about 18 years after
their exposure. Inclusion criteria were as follows: documen-
ted exposure to sulfur mustard; documented diagnosis of
chronic pulmonary lesions due to mustard; not being in a life
threatening situation; not smoking cigarettes or any kind ofdrugs; and not having pneumonia and/or acute bronchitis.
Exclusion criteria were: occurrence of any severe side
effects of NAC; using any kind of antioxidant drug; history of
resection of one or more lobes of lung; deterioration in
clinical conditions of patients during the course of the study;
and using less than 80% of the medication.
Before the trial, high resolution computed tomography
(HRCT) was taken from participants. Chest HRCT scans were
taken with high speed advantage scanner (General Electric
Medical System, Milwaukee, Wisconsin). It consisted of five
1.0mm collimation images obtained during deep inspiration
and full expiration, while patients were in supine position.
All chest HRCT scans were reviewed by a radiologist familiar
with BO cases. The expiratory images were assessed for the
presence of air trapping and lobar distribution of it defined
as alteration of normal anterior–posterior lobar attenuation
gradients and/or lack of homogenous increase in pulmonary
attenuation resulting in persistent areas of decreased
attenuation. The presence of air trapping was quantified
and was considered to be an indication of BO only if it
exceeded 25% of the cross-sectional areas of an affected
lung, in at least one scanned level.7 Participants were
randomly allocated to placebo or NAC group using random
number table. So we had two groups: NAC and placebo
groups. We enrolled 144 patients in this study. Each group
contained 72 patients.
All patients received NAC or placebo for 4 months. They
received 1800mg of NAC or placebo per day in three doses.
Patients were not allowed to use any other treatments
during the course of the trial expect for inhalatory Salmetrol
(50 mg, twice a day) and Flixotide (250 mg, twice a day).
Drugs were delivered to patients every 14 days, and their
using the medication was controlled by weekly phone
contacts. Patients were free to leave the study whenever
they wished to. Written informed contests were obtained
from all patients before the trial. The trial was approved of
by the ethical committee of research center of chemical
injuries.
All patients were visited by a general practitioner before
and after the trial in order for the clinical condition of each
patient to be assessed with especial emphasis on dyspnea,
wake-up dyspnea, cough, having sputum, and hemoptysis.
These signs and symptoms except for sputum and hemop-
tysis were quantified by a scale in which 1 denoted ‘‘no
problem’’ and 5 or 4 denoted ‘‘the worst condition’’ (4 for
wake up dyspnea and 5 for dyspnea and cough) which is
depicted in detail in Table 1. Sputum and hemoptysis were
reported as having sputum or hemoptysis or not. So we were
able to analyze the changes in clinical conditions in the
course of the trial in each placebo and NAC group in addition
to analyzing the differences between these two groups.
All participants underwent spirometry before the trial, in
the middle of the course of the trial (e.g. in month 2) and
just at the finishing of the trial (e.g. the fourth month after
the beginning of the trial). So we were able to analyze the
changes in lung function in the course of the trial in each
placebo and NAC group and also the differences between
these two groups. In this study, we only enrolled participants
who were in class 1 or 2 of bronchiolitis obliterans syndrome
(BOS 1 and BOS 2).20
We analyzed cough, dyspnea, wake-up dyspnea, and
sputum at the beginning of the trial between two groups
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placebo groups separately (McNemar for sputum, paired
t-test for others) and between groups after 4 months
(t-test). We also analyzed pulmonary function test; we
analyzed forced expiratory volume in 1 s (FEV1), forced vital
capacity (FVC), and FEV1/FVC during the course of the trial
in each group separately and also between groups during the
course of trial (repeated measure ANOVA).
Result
After 4 months of treatment, 68 patients remained in
placebo group and 70 in NAC group. People who left the
study were excluded from all analyses. Age did not differTable 1 Definition of scales which was used to quantify
cough, dyspnea and wake-up dyspnea.
Cough
1 I did not have cough
2 I have cough, but it is not a serious
problem
3 I have cough, sometimes disturbs
my work
4 I have disturbing cough, usually
disturbs my work
5 I have disturbing cough, always
disturbs my work
Dyspnea
1 There is no dyspnea
2 Dyspnea exists, only in
extraordinary exercises
3 Dyspnea exists in ordinary exercise
4 Dyspnea exists in mild exercise
5 Dyspnea exists in rest
Wake-up dyspnea
1 I have never waken up due to
dyspnea
2 I have waken up less than one time
per week
3 I have waken up one time per week
4 I have waken up more than two
times per week




Wake-up dyspnea 2.39 (0.97)
Sputumby 87.5% (63)
Hemoptysisy 5.6% (4)
The difference between two groups for each clinical condition was an
depicted in the rightmost column.
Data are depicted as mean (S.D.).
yData are depicted as percent (number) of patients did have sputusignificantly between two groups (mean ¼ 45.93 (S.D. ¼
10.09) years old in NAC, 47.19 (11.26) years old in placebo,
p ¼ 0.48, t-test). The number of men and women in each
group did not differ also (67% (46) men in placebo group; 70%
(49) men in NAC group, p ¼ 0.85 w2). Clinical characteristics
of both NAC and placebo groups at the beginning of the trial
are shown in Table 2. We did not analyze hemoptysis
because very few patients showed this symptom at the
beginning of the trial.Clinical data
Cough did not differ between the two groups at the
beginning of the trial (mean ¼ 2.88 (S.D. ¼ 0.65): placebo;
3.08 (0.76): NAC; t-test, p-value ¼ 0.097). Both NAC (3.07
(0.76): cough before the trial; 2.08 (0.40): cough after 4
months; paired t-test, p-value o0.001) and placebo (2.87
(0.64): cough before the trial; 2.25 (0.50): cough after 4
months; paired t-test, p-value o0.001) improved cough
after 4 months. In order to find out whether or not NAC was
more effective than placebo on cough after 4 months, we
compared ‘‘delta cough’’ (i.e. cough after 4 months—cough
before the trial) between the two groups. NAC was more
effective than placebo in treating cough (0.98 (0.83) for
NAC; 0.61 (0.86) for placebo, t-test, p-value ¼ 0.011).
Dyspnea was slightly worse in NAC group (mean ¼ 3.10
(S.D. ¼ 0.67): placebo; 3.38 (0.61): NAC; t-test, p-value ¼
0.014). NAC (3.37 (0.61): dyspnea before the trial; 2.62
(0.57): dyspnea after 4 months; paired t-test, p-value
o0.001) could improve dyspnea after 4 months but placebo
did not have such an effect (3.09 (0.66): dyspnea before the
trial; 2.94 (0.48): dyspnea after 4 months; paired t-test,
p-value ¼ 0.06). We computed ‘‘delta dyspnea’’ (i.e. dys-
pnea after 4 months—dyspnea before the trial) and
compared it between the two groups. NAC was more
effective than placebo in reducing dyspnea (0.74 (0.71)
for NAC; 0.14 (0.65) for placebo, t-test, p-value o0.001).
Wake-up dyspnea did not differ between groups
(mean ¼ 2.10 (S.D. ¼ 0.81): placebo; 2.39 (0.97): NAC;
t-test, p-value ¼ 0.06). NAC (2.37 (0.96): wake-up dyspnea
before the trial; 1.86 (0.51): wake-up dyspnea after 4
months; paired t-test, p-value o0.001) improved cough
after 4 months but placebo did not show such an effect (2.07
(0.78): wake-up dyspnea before the trial; 1.88 (0.56): wake-
up dyspnea after 4 months; paired t-test, p-value ¼ 0.068).ps at the beginning of the trial before drug administration.
Placebo Analysis
2.88 (0.65) t-Test, p ¼ 0.097
3.10 (0.67) t-Test, p ¼ 0.014
2.10 (0.81) t-Test, p ¼ 0.06
79.4% (54) w2, p ¼ 0.1
2.9% (2) w2, p ¼ 0.43
alyzed separately. The test applied and the significance level was
m or hemoptysis.
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Figure 1 The upper part represented the mean of FEV1 in NAC
group (red, continues line) and placebo group (blue, dashed
line) at the beginning (month 0), after 2 months of the
beginning of the trial (month 2) and after 4 months of the
beginning of the trial (month 4). The table in the lower part
reports the mean (S.D.) of FEV1 in both groups over time.
M. Shohrati et al.446We computed delta ‘‘wake-up dyspnea’’ (i.e. wake-up
dyspnea after 4 months—wake-up dyspnea before the
trial) and compared it between the two groups. NAC was
more effective than placebo in reducing wake-up dyspnea
(0.50 (0.87) for NAC; 0.19 (0.85) for placebo, t-test,
p-value ¼ 0.036).
Sputum did not differ between the two groups at the
beginning of the trial when 87.5% (63) in NAC and 79.4% (54)
in placebo group revealed this symptom (w2, p-value ¼ 0.1).
After 4 months, NAC reduced sputum (87.5% (63) before the
trial, 55% (39) before the trial, McNemar, po0.001) but
placebo did not (79.4% (54) before the trial, 72% (49) after
the trial, McNemar, p ¼ 0.64).
Pulmonary function test (PFT) data
FEV1
Applying repeated measure ANOVA (General Linear Model) in
which the changes of both groups were compared, there
were not any significant differences between these changes
over the course of trial (p ¼ 0.372). But FEV1 changed
significantly over time in NAC group (repeated measure
ANOVA, General Linear Model, po0.001), but not in the
placebo group (p ¼ 0.164). Considering the differences of
FEV1 in both groups at the beginning of the trial in regression
model, NAC significantly improved FEV1 over placebo after 4
months (po0.001). The mean (S.D.) of FVC in both groups
during the trial is depicted in Figure 1.
FVC
Applying repeated measure ANOVA (General Linear Model) in
which the changes of both groups were compared, there
were not any significant differences between these changes
over the course of trial (p ¼ 0.610). But FVC changed
significantly over time in NAC group (repeated measure
ANOVA, General Linear Model, p ¼ 0.004), but not in the
placebo group (p ¼ 0.743). Considering the differences of
FVC in both groups at the beginning of the trial in regression
model, NAC significantly improved FVC over placebo after 4
months (p ¼ 0.044). The mean (S.D.) of FEV1 in both groups
during the study is depicted in Figure 2.
FEV1/FVC
Applying repeated measure ANOVA (General Linear Model) in
which the changes of both groups were compared, there
were not any significant differences between these changes
over the course of trial (p ¼ 0.317). But FEV1/FVC changed
significantly over time in NAC group (repeated measure
ANOVA, General Linear Model, po0.001), but not in the
placebo group (p ¼ 0.149). Considering the differences of
FEV1/FVC in both groups at the beginning of the trial in
regression model, NAC significantly improved FEV1/FVC over
placebo after 4 months (po0.001). The mean (S.D.)
of FEV1/FVC in both groups during the trial is depicted in
Figure 3.
Discussion
In our study, we found out that NAC could improve not only
clinical signs and symptoms of patients with mustard
induced bronchiolitis obliterans, but also parameters ofpulmonary function test. These findings are more interesting
when we consider the time of the exposure to sulfur mustard
and the time of the administration of NAC, i.e. a gap of 18
years and only a treatment of 4-month’s time.
Previous studies showed that NAC could be effective in
the treatment of and controlling clinical conditions in COPD
patients by its antioxidative properties.21–23 It could reduce
bronchial infections24 and exacerbations25 in these patients
too. It seems that NAC interacts with inflammatory
processes underlying the pathophysiology of COPD.26–28
We administered NAC or placebo in combination with
Flixotide and Salmetrol. Because both groups received
Flixotide and Salmetrol, we could not rule out the possibility
of the synergistic effects of NAC and these medications. We
suggest that this possibility should be slim because previous
results of our clinic showed that Flixotide and Salmetrol had
improving effects on only 27% of the studied population of
patients with the same conditions as this study.29 So,
planning a clinical trial with NAC administration without
any other types of medications would clear this ambiguity.
Our data showed that NAC is also effective in treating
bronchiolitis caused by mustard exposure. NAC could
produce effects by preventing the release of many inflam-
matory mediators in different pathological conditions.10 It
could prevent bronchiolitis in mice which were exposed to
cigarette smoke.30 NAC could reduce the level of TNF-a in
lung transplanted persons.31 It also reduces the secretion of
many inflammatory modulators (e.g. Ref. 32). Just the
same, by acting on bronchial smooth muscles, it could
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Figure 3 The upper part represented the mean of FEV1/FVC in
NAC group (red, continues line) and placebo group (blue,
dashed line) at the beginning (month 0), after 2 months of the
beginning of the trial (month 2) and after 4 months of the
beginning of the trial (month 4). The table in the lower part
reports the mean (S.D.) of FEV1/FVC in both groups over time.
Figure 2 The upper part represented the mean of FVC in NAC
group (red, continues line) and placebo group (blue, dashed
line) at the beginning (month 0), after 2 months of the
beginning of the trial (month 2) and after 4 months of the
beginning of the trial (month 4). The table in the lower part
reports the mean (S.D.) of FVC in both groups over time.
Effects of N-acetyl cysteine on mustard gas exposed patients 447prevent thickening of respiratory airways and bronchial
smooth muscle hypertrophy.33
So NAC could reduce the inflammation in respiratory
system by characteristics mentioned above and our results
are also in line with the effectiveness of NAC in treating
bronchiolitis due to sulfur mustard exposure. It is concor-
dant with the evidence that showed the effectiveness of
antioxidants in preventing sulfur mustard induced oxidative
stress.34,35 It is also in harmony with the outcomes of the
experimental studies. NAC could protect bronchial epithelial
cells against sulfur mustard in vitro.17,36 NAC could also
treat acute lung injuries induced by mustard gas in rat
model.37 So NAC not only can be used in treating bronchitis,
but also in treating Bronchiolitis; not only in preventing
mustard induced oxidative stress, but also in treating
mustard induced pulmonary lesions.
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